palbociclib (PD-0332991)
Showing 1 - 25 of 6,778
Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer Trial in Boston (Palbociclib, Gedatolisib)
Recruiting
- Lung Cancer Squamous Cell
- +3 more
-
Boston, Massachusetts
- +2 more
Jan 9, 2023
Head Neck Cancer, Locally Advanced Trial in Bangkok (Palbociclib, Cetuximab, Intensity Modulated Radiation Therapy)
Active, not recruiting
- Head and Neck Cancer
- Locally Advanced
- Palbociclib
- +2 more
-
Bangkok, ThailandFaculty of Medicine, Ramathibodi Hospital
Sep 19, 2022
Advanced Breast Cancer Trial in Dallas (PD-0332991 and T-DM1)
Completed
- Advanced Breast Cancer
- PD-0332991 and T-DM1
-
Dallas, TexasUT Southwestern Medical Center
Jan 24, 2022
KRAS Mutant NSCLC, Solid Tumors Trial in Boston (Palbociclib, PD-0325901)
Active, not recruiting
- KRAS Mutant Non-Small Cell Lung Cancer
- Solid Tumors
-
Boston, MassachusettsDana Farber Cancer Institute
Jan 18, 2022
Carcinoma, Squamous Cell of Head and Neck Trial in United States (Cetuximab, PD 0332991)
Active, not recruiting
- Carcinoma, Squamous Cell of Head and Neck
- Cetuximab
- PD 0332991
-
Atlanta, Georgia
- +4 more
Nov 1, 2022
Malignant Female Reproductive System Tumor, Malignant Solid Tumor, Recurrent Malignant Female Reproductive System Tumor Trial
Not yet recruiting
- Malignant Female Reproductive System Neoplasm
- +3 more
- Biopsy
- +7 more
- (no location specified)
Nov 9, 2023
Malignant Solid Tumor, Ovarian Low Grade Serous Adenocarcinoma, Pancreatic Carcinoma Trial (Binimetinib, Biopsy, Biospecimen
Not yet recruiting
- Malignant Solid Neoplasm
- +4 more
- Binimetinib
- +6 more
- (no location specified)
Nov 8, 2022
Colorectal Carcinoma, Lung Adenocarcinoma, Malignant Solid Tumor Trial in Buffalo (Binimetinib, Palbociclib, Therapeutic
Recruiting
- Colorectal Carcinoma
- +3 more
- Binimetinib
- +2 more
-
Buffalo, New YorkRoswell Park Cancer Institute
May 11, 2022
Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma
Not yet recruiting
- Advanced Dedifferentiated Liposarcoma
- +5 more
- Palbociclib
- +5 more
- (no location specified)
Jan 11, 2023
Metastatic Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7 Trial in United States (drug, other, biological)
Suspended
- Metastatic Breast Carcinoma
- Stage IV Breast Cancer AJCC v6 and v7
- Fulvestrant
- +4 more
-
Corona, California
- +6 more
Sep 28, 2022
Renal Cell Carcinoma Trial in Macquarie University, Haifa (Belzutifan, Palbociclib)
Recruiting
- Renal Cell Carcinoma
-
Macquarie University, New South Wales, Australia
- +1 more
Aug 15, 2022
Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,
Recruiting
- Advanced Malignant Solid Neoplasm
- +9 more
- Everolimus
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Oct 25, 2022
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Philadelphia (Palbociclib, Tazemetostat,
Not yet recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Palbociclib
- +4 more
-
Philadelphia, PennsylvaniaThomas Jefferson University Hospital
Jan 13, 2023
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial
Active, not recruiting
- Anatomic Stage I Breast Cancer AJCC v8
- +20 more
- Hydroxychloroquine
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 12, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 Trial in Houston
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +2 more
- Abemaciclib
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Oct 25, 2022
Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in
Recruiting
- Recurrent Acute Lymphoblastic Leukemia
- +3 more
- Decitabine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jun 29, 2022
Breast Cancer Trial in United States (Palbociclib, Aromatase Inhibitor)
Completed
- Breast Cancer
- Palbociclib
- Aromatase Inhibitor
-
San Francisco, California
- +9 more
Mar 18, 2022
Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma Trial in Los Angeles (procedure, drug, other)
Terminated
- Estrogen Receptor Positive
- +16 more
- Biopsy of Breast
- +5 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Sep 22, 2022
Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (drug, radiation, procedure)
Active, not recruiting
- Head and Neck Squamous Cell Carcinoma
- Palbociclib
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Feb 25, 2022
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant
Withdrawn
- Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
- +3 more
- Abemaciclib
- +3 more
- (no location specified)
Oct 13, 2021
Solid Tumor, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer Trial in Atlanta (Carboplatin, Cisplatin, Palbociclib)
Active, not recruiting
- Solid Neoplasm
- +16 more
- Carboplatin
- +2 more
-
Atlanta, GeorgiaEmory University/Winship Cancer Institute
Feb 28, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative Trial in United States (Anastrozole,
Active, not recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +6 more
- Anastrozole
- +6 more
-
Atlanta, Georgia
- +9 more
Oct 12, 2022